Correspondence on 'Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort'

Ann Rheum Dis. 2021 Oct;80(10):e159. doi: 10.1136/annrheumdis-2021-220539. Epub 2021 May 24.

Authors

Giuseppe A Ramirez^#^{1

2}, Emanuel Della-Torre^#^{3

2}, Luca Moroni^#^{3

2}, Mona-Rita Yacoub^{3

2}, Lorenzo Dagna^{3

2}; OSR-COVAX study group

Collaborators

OSR-COVAX study group:
Elena M Baldissera, Enrica P Bozzolo, Nicola Boffini, Giulia Di Colo, Corrado Campochiaro, Adriana Cariddi, Giacomo De Luca, Matteo Bellone, Silvia Sartorelli, Angelo A Manfredi, Giulio Cavalli, Alessandro Tomelleri, Chiara Asperti, Gaia Mancuso, Nicola Farina, Ambra Mascheri, Nicoletta Saporiti

Affiliations

¹ Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS Ospedale San Raffaele, Milano, Italy [email protected].
² Immunology, Università Vita Salute San Raffaele, Milano, Italy.
³ Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS Ospedale San Raffaele, Milano, Italy.

^# Contributed equally.

PMID: 34031031
DOI: 10.1136/annrheumdis-2021-220539

No abstract available

Keywords: COVID-19; autoimmune diseases; immune system diseases; vaccination.

Publication types

Letter
Comment

MeSH terms

COVID-19 Vaccines*
Cohort Studies
Humans
Immunogenicity, Vaccine
Immunosuppression Therapy*
RNA, Messenger

Substances

COVID-19 Vaccines
RNA, Messenger